Mirvetuximab Soravtansine (ELAHERE) PopPK
Indication: FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
Population PK simulator for mirvetuximab soravtansine (ELAHERE, IMGN853) — FRα-targeted ADC with DM4 maytansinoid payload for platinum-resistant ovarian cancer. Two-compartment ADC model with albumin covariate on clearance and AIBW-based dosing. The first ADC to show OS benefit vs chemotherapy in a solid tumor (MIRASOL trial). Based on Choudhry et al. CPT 2023 and FDA Clinical Pharmacology Review.
Drug Overview
Clinical Context
- Molecular Target
- FRα (Folate Receptor Alpha, FOLR1)
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology / Ovarian Cancer
- Indication
- FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
- Route of Administration
- IV Infusion
Model Information
- Model Type
- Population PK (2-CMT ADC + 1-CMT DM4 Payload)
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
Additional Parameters
| Parameter | Value |
|---|---|
| k12 | 0.22 |
| k21 | 0.3 |
| ADC CL | 0.65 |
| DM4 Vd | 420 |
| Standard Dose | 6 |
| DM4 Payload CL | 38 |
| ADC V1 (Central) | 3.8 |
| ADC V2 (Peripheral) | 2.1 |
| Albumin Exponent on CL | 0.45 |
| Payload Release Rate (kr) | 0.008 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Mirvetuximab Soravtansine (ELAHERE) allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK (2-CMT ADC + 1-CMT DM4 Payload) model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Mirvetuximab Soravtansine (ELAHERE) PK simulator?
This is a free, interactive pharmacokinetic simulator for Mirvetuximab Soravtansine (ELAHERE) used in FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Mirvetuximab Soravtansine (ELAHERE) belong to?
Mirvetuximab Soravtansine (ELAHERE) is classified as a Antibody-Drug Conjugate (ADC) that targets FRα (Folate Receptor Alpha, FOLR1). It is used in the Oncology / Ovarian Cancer therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of Mirvetuximab Soravtansine (ELAHERE). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK (2-CMT ADC + 1-CMT DM4 Payload) model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Patritumab Deruxtecan (HER3-DXd) PopPK
EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
T-DXd (Enhertu) PBPK-PD ILD Risk Simulator
HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization
Ready to Simulate?
Launch the Mirvetuximab Soravtansine (ELAHERE) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community